Lilly's lasmiditan passes second Phase III test

Eli Lilly and Co. (NYSE:LLY) said lasmiditan (oral COL-144) met the primary endpoint in a second Phase III trial to treat acute migraine. In 2H18, the pharma plans to submit an NDA to FDA for the candidate.

In the Phase III SPARTAN trial, a significantly greater proportion of patients who received a single dose of 50, 100 and 200 mg oral lasmiditan were free of migraine headache pain at two hours post-dose vs. placebo (28.6%, 31.4% and 38.8%, respectively, vs. 21.3%, p=0.003, p<0.001 and p<0.001)...